Hyloris Submits Additional Data For Maxigesic IV Filing To US FDA

Firm Received Pushback From FDA On Product’s Packaging

 
• By Chloe Kent
  
Entrance to FDA headquarters in Maryland
The FDA had additional questions about the vial and stopper of the Maxigesic IV packaging • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

More from Products